Clinical Trial Update: Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ribociclib plus belinostat for metastatic triple-negative breast cancer and recurrent ovarian cancer, with genomic markers used to pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Belinostat (belinostat)
• Ribociclib (ribociclib)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Breast Cancer, Recurrent Ovarian Carcinoma | Phase 1 | Status: RECRUITING